Table 1

Summary of study methodology
V vs F vs P (n = 4) V vs F (n = 8) V vs P (n = 10) F vs P (n = 9) Total (n = 31)
Year (1999, 2003, 2004, 2009) (1994, 1997, 1998, 2000, 2007) (1993, 1996, 1997, 1998, 2004) (1991, 1998, 2002, 2004, 2005) (1991, 1997, 1999, 2003, 2009)
Anxious depression (No) 3 (75%) 7 (88%) 10 (100%) 8 (89%) 28 (90%)
Study duration (weeks) (6, 6, 8, 12) (6, 8, 9, 12, 12) (4, 6, 8, 11, 13) (4, 6, 8, 12, 13) (4, 6, 8, 12, 13)
Number of follow-up visits (6, 7, 8, 8) (6, 6, 7, 8, 9) (NA = 1) (5, 6, 7, 8, 8) (3, 8, 9, 9, 9) (NA = 1) (3, 6, 7, 8, 9) (NA = 2)
Industry sponsorship (yes) 4 (100%) 8 (100%) 10 (100%) 8 (100%) (NA = 1) 30 (100%) (NA = 1)
Exclusion of placebo responders (yes) 4 (100%) 5 (63%) 10 (100%) 6 (75%) (NA = 1) 25 (83%) (NA = 1)
Patient type (NA = 1) (NA = 1) (NA = 2)
 Inpatients 1 (25%) 2 (25%) 1 (11%) 1 (12.5%) 5 (17%)
 Outpatients 3 (75%) 5 (63%) 7 (78%) 6 (75%) 21 (73%)
 Outpatients in primary care 0 (0%) 1 (12%) 1 (11%) 1 (12.5%) 3 (10%)
Scale used
 HDRS 4 (100%) 5 (63%) 4 (40%) 8 (89%) 23 (74%)
 MADRS 0 (0%) 3 (37%) 6 (60%) 1 (11%) 8 (26%)
Type of analysis
 ITT with LOCF 4 (100%) 8 (100%) 10 (100%) 8 (89%) 30 (97%)
 Mixed model 0 (0%) 0 (0%) 0 (0%) 1 (11%) 1 (3%)
Initial severity (HDRS score 25) 3 (75%) 5 (63%) 6 (60%) 3 (37.5%) (NA = 1) 17 (57%) (NA = 1)

n, number of studies. Results are presented in (minimum, first quartile, median, third quartile, maximum) for quantitative data except for V vs F vs P where all the data are given. Qualitative data are presented as a number (percentage). NA represents the number of studies where data were unavailable.

V vs F vs P: studies comparing venlafaxine to fluoxetine to placebo.

V vs F: studies comparing venlafaxine to fluoxetine.

V vs P: studies comparing venlafaxine to placebo.

F vs P: studies comparing fluoxetine to placebo.

HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale.

Naudet et al.

Naudet et al. BMC Medicine 2013 11:230   doi:10.1186/1741-7015-11-230

Open Data